Genetic Analysis

Name

Genetic Analysis

Legal name

Genetic Analysis AS

Website

https://genetic-analysis.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Microbiome Diagnostics

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH)

akta.pro secondary industries

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Microbiome diagnostics
• Gut microbiota testing
• Molecular diagnostics kits
• IVD reagent kits
• Dysbiosis clinical testing

Headquarters

HQ city

Oslo

HQ country

Norway

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

1. GA-map® Dysbiosis Test Reagent Kit Sales: Sale of CE-marked reagent kits to diagnostic laboratories for their own use on Luminex instruments. Recurring revenue from reagent kit sales as labs perform tests. The company experienced 37% growth in reagent kit sales YTD December 2024 compared to 2023, and 13% growth in Q4 2025 reagent kit sales.
2. Service Laboratory Testing: GA analyzes samples at its Oslo service laboratory and sends encrypted reports back to routine diagnostic laboratories. Fecal samples are collected locally, assembled by laboratories, and sent batchwise for analysis. This model generates revenue per test performed.
3. Ferring Collaboration (MHI GutHealth): Revenue from collaboration with Ferring Pharmaceuticals to develop and launch the GA-map® MHI GutHealth test. GA has exclusive commercialisation rights with no obligations to pay running royalties or milestones to Ferring. Revenue will be generated based on number of tests sold.
4. Thalys Partnership (China Market): Supply of reagent kits to Thalys Medical Technology Group for Chinese Consumer Health market testing. Revenues generated based on number of tests sold through the D2C platform.
5. IBD Precision Dx Development: Development of diagnostic test for predicting disease course in ulcerative colitis patients, conducted in collaboration with Scandinavian university hospitals and funded by the Research Council of Norway. Expected to serve as additional growth driver upon launch in H1-26.

Pricing tiers

Go-to-market motion4 records

Distribution channels7 records

Marketing channels6 records

Core offering

Genetic Analysis AS operates the GA-map® platform, a CE-marked IVD molecular diagnostic system for gut microbiota profiling. The company develops, manufactures, and sells reagent kits and assay protocols for use on standard Luminex instruments, enabling diagnostic laboratories to identify dysbiosis in patients with IBS and IBD. In parallel, it runs a centralized GA-map® Service Laboratory in Oslo and licenses its proprietary algorithm and AI-assisted AInsight interpretation software to support clinical decision-making and pharmaceutical companion-diagnostics programs.

Product overview

Genetic Analysis offers a platform-plus-products architecture centered on the GA-map® technology platform for microbiome diagnostics. The core platform consists of the GA-map® Dysbiosis Test Lx, a CE-marked IVD test for gut microbiota profiling in IBS/IBD patients that runs on Luminex instruments, and the GA-map® COVID-19 Fecal Test Kit. The reagent kit products (GA-map® Dysbiosis Test Reagent Kit, COVID-19 Reagent Kit) enable labs to run tests on-site, while the GA-map® Service Laboratory offers centralized testing. Additional modules include GA-map® MHI GutHealth (with Ferring Pharmaceuticals), GA-map® Discovery (research market), GA-map® IBD Precision Dx (in development), and AInsight (AI-assisted interpretation). The portfolio spans clinical diagnostics, clinical research, and companion diagnostics applications.

Differentiator

Problem solved

Functional benefit

Brands

• GA-map: Proprietary diagnostic technology platform for characterization of the human microbiome, including probe-based gut microbiota tests on Luminex instruments with standardized dysbiosis testing for IBS and IBD patients.

Products and services

• GA-map® Dysbiosis Test Lx A CE-marked IVD molecular diagnostic test for profiling gut microbiota dysbiosis in patients with IBS and IBD, designed to be run on standard Luminex bead-based instruments in routine diagnostic laboratories. It is the first CE-marked IVD test for gut microbiota dysbiosis and is used by clinical labs needing a reproducible, regulatory-cleared microbiome assay.
• GA-map® Dysbiosis Reagent Kit A CE-IVD marked reagent kit (consumable) that enables diagnostic laboratories to perform the GA-map® Dysbiosis Test on their existing Luminex instruments. Sold as a recurring consumable product, it forms the core reagent revenue stream for Genetic Analysis.
• GA-map® COVID-19 Fecal Test Kit A PCR-based fecal test kit for the detection of SARS-CoV-2 in stool samples, developed and launched in response to the COVID-19 pandemic. It enables laboratories to perform non-invasive COVID-19 testing and to study viral persistence in the gut.
• GA-map® COVID-19 Reagent Kit A qPCR reagent kit (consumable) that supports the GA-map® COVID-19 Fecal Test workflow for SARS-CoV-2 detection in stool samples. Sold to diagnostic laboratories as a recurring consumable kit.
• GA-map® MHI GutHealth A Research-Use-Only (RUO) gut health profiling assay that allows researchers and clinical investigators to characterize gut health using the GA-map® platform on Luminex instruments. It serves academic and translational research customers who do not require an IVD-marked test.
• GA-map® Discovery Reagent Kit A research-use reagent kit targeting more than 170 bacteria, designed for research and discovery applications that require broad bacterial coverage in a single workflow. It supports academic and industrial microbiome research projects using the GA-map® chemistry.
• GA-map® Service Laboratory A centralized diagnostic testing service operated from Oslo, Norway, that performs the GA-map® Dysbiosis Test on behalf of customers who prefer outsourced sample testing. It supports laboratories and clinicians that want standardized gut microbiota profiling without running the assay in-house.
• GA-map® AInsight An AI-powered interpretation platform integrated into the GA-map® product line. AInsight uses a Large Language Model (LLM) to assist clinicians and laboratory customers in interpreting GA-map® test results, drawing on the proprietary Bacteria Compendium and dysbiosis index outputs from the algorithm.

Quantifiable outcome

• 37% growth in GA-map Dysbiosis Test reagent kit sales in 2024 compared to 2023
• +4 more outcomes

Named customers12 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature6 records

Partnerships

20 partnerships are on record, tiered major, flagship, core, standard and minor.

• Pangea Laboratory LLCmajorChannel Partner/ Reseller/ Distributor · 29 July 2025US partner for launch of GA-map MHI GutHealth in the USA market.
• Ferring PharmaceuticalsflagshipStrategic or Co-development Partner · 20 December 2024Collaboration to develop and launch GA-map MHI GutHealth rapid diagnostic test combining GA's PCR platform with Ferring's Microbiome Health Index biomarker. GA has exclusive commercialisation rights with no royalties or milestones to Ferring. Test launched H1-2025 as Research Use Only product.
• ProkarimimajorChannel Partner/ Reseller/ Distributor · 8 August 2024Launched DTC platform for Gut Microbiome testing in Norway powered by GA-map technology.
• Thalys Medical Technology GroupflagshipStrategic or Co-development Partner · 13 January 2022Laboratory Developed Test agreement for Chinese market using GA-map technology. Thalys uses Shanghai-based Independent Clinical Lab to develop and distribute tests. April 2025 launch of consumer health microbiome test via D2C mobile software platform.
• Eurofins ADME BIOANALYSESmajorChannel Partner/ Reseller/ Distributor · 19 October 2021Service agreement with CRO to offer GA-map Dysbiosis Test to pharmaceutical and clinical research customers. First CRO to offer GA-map microbiome test, enhancing Eurofins' microbiome service offering.
• Luminex InccoreTechnology or IntegrationIndustrial partnership for technology platform. GA-map tests are designed for use on Luminex instruments (Luminex 200 and MAGPIX), utilizing xMAP Technology for multiplexed detection of bacteria targets.
• Bio-Rad IncmajorChannel Partner/ Reseller/ DistributorUS distribution partner for GA-map products. Bio-Rad also participated as subscriber in May 2025 directed share issue with NOK 4,693,500 investment.
• Eagle BioSciences IncstandardChannel Partner/ Reseller/ DistributorUS distribution partner for GA-map microbiome products in North America.
• BIOHIT OyjstandardChannel Partner/ Reseller/ DistributorFinnish distributor for GA-map products in Finland.
• BIOHIT HealthCare LtdstandardChannel Partner/ Reseller/ DistributorUK distributor for GA-map products.
• BIOHIT HealthCare SrlstandardChannel Partner/ Reseller/ DistributorItalian distributor for GA-map products.
• ARIUM Sistemas de Diagnóstico Lda.standardChannel Partner/ Reseller/ DistributorPortuguese distributor for GA-map products.
• Oslo University HospitalcoreStrategic or Co-development PartnerCollaborating partnership in Scandinavia for clinical research and product development related to GA-map technology and microbiome diagnostics.
• Sahlgrenska Academy (University of Gothenburg)coreStrategic or Co-development PartnerSwedish academic research partner collaborating on microbiome research and GA-map technology development.
• Skåne University Hospital (Lund University)coreStrategic or Co-development PartnerSwedish collaborating partnership for clinical research and microbiome diagnostics development.
• Haukeland University HospitalcoreStrategic or Co-development PartnerNorwegian hospital partner and current partner on GA-map COVID-19 Fecal Test project.
• Helse-FonnaminorStrategic or Co-development PartnerNorwegian healthcare partner collaborating on microbiome research.
• UNN (University Hospital of North Norway)minorStrategic or Co-development PartnerNorwegian hospital partner for microbiome research collaboration.
• Nordsjællands HospitalminorStrategic or Co-development PartnerDanish hospital collaborating partner for microbiome research.
• Helsinki University HospitalminorStrategic or Co-development PartnerFinnish hospital collaborating partner for microbiome research.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Microba Life Sciences: Australia-based gut microbiome testing and analysis company offering metagenomic profiling and microbiome insights to clinicians, researchers, and consumers. Directly comparable to GA in targeting the gut microbiome diagnostics opportunity, though Microba leans on shotgun metagenomics rather than GA's probe-based PDT approach.
• ZOE: Consumer-focused gut microbiome testing and personalised nutrition company using shotgun metagenomics to deliver diet guidance. Comparable in addressing the same gut-health clinical question for IBS/IBD-adjacent consumers, but operating in a pure D2C, consumer subscription model versus GA's lab-channel core.
• Viome Life Sciences: Direct-to-consumer microbiome testing company using metatranscriptomic analysis to provide personalised nutrition and supplement recommendations. Competes with GA's consumer-channel ambitions (e.g. Thalys in China, Prokarimi in Norway), although Viome is consumer-led while GA's centre of gravity is clinical labs.
• DayTwo: Personalised nutrition company that provides gut-microbiome-based dietary recommendations for managing metabolic conditions. Overlaps with GA's nutritionist customer segment and gut-health use case, but DayTwo is more consumer/employer-benefit oriented and uses NGS-based analysis.

Emerging players

• CosmosID: Microbiome genomics services company providing NGS-based pathogen detection, microbiome profiling, and bioinformatics to clinical, industrial, and research customers. Compares to GA's research-market (GA-map Discovery) and service-lab offering, though CosmosID operates a different technology stack.
• MaaT Pharma: Late-stage clinical microbiome therapeutics company developing FMT-based and defined-consortium therapies, including for rCDI. Comparable to GA in addressing the same gut-microbiome clinical rationale (including rCDI, the validation population for MHI GutHealth), but MaaT is on the therapeutic rather than diagnostic side.
• Seres Therapeutics: Microbiome therapeutics company with an approved rCDI product (Vowst) and other pipeline programmes. Comparable in addressing the same clinical opportunity as GA's MHI GutHealth rCDI assay and companion-diagnostics franchise, but on the drug rather than diagnostic side.
• Rebiotix (a Ferring company): Ferring-owned microbiome therapeutics business that developed the RBX2660 (Rebyota) FMT therapy for rCDI. Highly comparable in addressing the rCDI market that underpins GA's MHI GutHealth collaboration with Ferring, and the parent relationship makes Rebiotix a critical counterparty for GA's franchise.

Broad incumbents

• Genova Diagnostics: Specialty clinical laboratory offering comprehensive stool-based and other functional medicine diagnostics to clinicians and consumers globally. Comparable as a broader-spectrum lab that competes with GA's dysbiosis test in the gastroenterology and functional-medicine prescribing workflow, though Genova offers a much wider test menu.
• Bio-Rad Laboratories: Global life science tools and clinical diagnostics company and GA's US distribution partner and largest investor. Comparable as a broad incumbent in clinical diagnostics and microbiome research reagents, while also being a strategic counterparty whose commercial decisions materially shape GA's US trajectory.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/GeneticAnalysis
• Facebookfacebook.com/geneticanalysis
• LinkedInlinkedin.com/company/genetic-analysis-as

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds3 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genetic Analysis